Spark Therapeutics Tops $1 Billion in Financing with Latest Public Offering

September 1, 2017: By Joan McKenna

SparkSpark Therapeutics has raised about $380.4 million in a public offering of 5.3 million shares of common stock, the Philadelphia gene therapy company announced Aug. 9.

The company says it has now secured $1 billion in total financing. Spark was founded in March 2013.

It is developing gene therapies that address inherited retinal diseases, neurodegenerative diseases, and diseases that can be addressed by targeting the liver, such as hemophilia.

Spark’s most advanced candidate, with the proposed trade name Luxturna (voretigene neparvovec), is currently under priority review with the US FDA for the treatment of biallelic RPE65-mediated inherited retinal disease. The company has filed for marketing approval with the EMA for the treatment of vision loss due to Leber congenital amaurosis or retinitis pigmentosa caused by confirmed biallelic RPE65 mutations. Luxturna has received breakthrough therapy and orphan status from the FDA, as well as orphan status from the EMA. Spark’s pipeline also includes SPK-7001 in an ongoing Phase I/II clinical trial for choroideremia.

J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and Cowen and Company, LLC, acted as book-running managers for the offering.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Imprimis’ Q3-2017 Ophthalmic Revenues Increase 60 Percent, Total $4.9 Million

iVeena Completes Phase I/IIa Study of IVMED-10 for Post-Cataract Inflammation

RegeneRx Announces Positive Phase III Results for RGN-259 in Dry Eye

Bill Link, PhD, Joins LENSAR as Board Chairman

Apellis Prices $150 Million Initial Public Offering

Oculentis Recalls Lentis IOLs in Philippines Due to Reports of Postoperative Opacification

Valeant Reports 1 Percent Growth for Bausch + Lomb Segment in Q3-2017

Tivanisiran is Generic Name for Sylentis’ Dry Eye Candidate

Alimera’s Q3-2017 Revenues Increased 18 Percent; Company Sees Expanded Market for Iluvien

Iridex’ Revenues Increase 11 Percent in Q3-2017; 111 Cyclo G6 Systems, 7,800 G6 Probes Shipped

Glaukos’ Net Sales Increase 37 Percent in Q3-2017

Regeneron’s US Eylea Sales Increase 12 Percent in Q3-2017

Second Sight Reports Q3-2017 Net Sales of $1.6 Million, New $122,500 CMS Rate for Argus II

Tear Film Innovations, Exicure, Genisphere Complete Financing Rounds

Opternative Sues Warby Parker Over Online Eye Exams

Bausch + Lomb Receives US FDA Approval for Vyzulta for IOP Reduction in Glaucoma Patients

Allergan Plans Cost Cuts, Takes Impairment Charge as Restasis Generics Loom

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022